Cardinal Health, Inc.

🇺🇸New York Stock Exchange
Back to all articles
Cardinal Health, Inc. stock analysis CAH overview
Somewhat Bullish +45

Cardinal Health (CAH) Stock Could Be 7.2% Undervalued After Guidance Raise - simplywall.st

📈 Cardinal Health reported an 11% year-over-year revenue increase alongside a raise in fiscal 2026 non-GAAP EPS guidance.

💰 The stock has gained 16.66% over the past 30 days and delivered a 39.64% total shareholder return over the last year.

🎯 Analyst consensus price target is $245.27, implying a potential 7.2% upside from the recent close of $227.72.

⚖️ The company trades at a P/E ratio of 34.3x, which exceeds the US healthcare industry average of 23.2x and peer average of 25.9x.

🛡️ Analysts have identified a bullish price target of $275.00 and a bearish target of $215.00, highlighting valuation disagreement.

⚠️ Key risks include tighter regulation, increased pricing scrutiny, and the potential loss of major customer contracts.

📉 If market sentiment cools, the high P/E multiple could lead to price adjustments rather than earnings compression.

💊 Stronger demand for high-margin specialty drugs is cited as a key driver supporting recent stock momentum.

Bullish Signals
  • Cardinal Health achieved an 11% year-over-year revenue increase, demonstrating solid top-line growth.
  • The company raised its fiscal 2026 non-GAAP EPS guidance, signaling confidence in future profitability.
  • Strong price action with a 30-day return of 16.66% and a one-year total shareholder return of 39.64% indicates building momentum.
  • Analyst consensus fair value of $245.27 suggests the stock is currently trading at a discount relative to growth expectations.
  • Increased demand for high-margin specialty drugs provides a favorable tailwind for the company's core business segments.
Risk Factors
  • The current P/E ratio of 34.3x is significantly higher than the US healthcare industry average of 23.2x and peer average of 25.9x, creating valuation risk.
  • Tighter regulation and increased pricing scrutiny pose potential threats to future revenue growth and margins.
  • The loss of major customer contracts could materially impact the company's revenue stability and growth trajectory.
  • Analyst disagreement on price targets, ranging from $215.00 to $275.00, indicates uncertainty regarding the stock's long-term valuation.
Full Analysis
Cardinal Health (CAH) recently reported an 11% year-over-year revenue increase and raised its fiscal 2026 non-GAAP earnings per share (EPS) guidance. These developments have coincided with stronger demand for high-margin specialty drugs, driving renewed investor attention to the stock. The positive momentum is reflected in strong price action, with Cardinal Health posting a 30-day share price return of 16.66% and a one-year total shareholder return of 39.64%. Analysts maintain a consensus price target of $245.27 against a recent closing price of $227.72, suggesting the stock could be undervalued by approximately 7.2% based on specific growth and margin assumptions. However, valuation concerns persist as the company trades at a P/E ratio of 34.3x, which is significantly higher than the US healthcare industry average of 23.2x and peer group average of 25.9x. While analysts see upside potential ranging from $215 to $275 per share, risks include tighter regulation, pricing scrutiny, and the potential loss of major customer contracts that could challenge future growth. The article concludes by weighing the optimism around steady revenue gains and modest margin improvement against the risk of a market correction if sentiment cools. Investors are advised to consider whether the current premium multiple is justified given the company's exposure to regulatory headwinds and competitive pressures in the specialty drug sector.